UPDATE On ENV105: Safety Lead-In Completed for This Innovative Therapy
/0 Comments/in Clinical Trial, Metastatic, Phase 2/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
225Ac abiraterone acetate ADC ADT AI ai in healthcare alphafold antibody-drug conjugate apalutamide artificial intelligence ATM bispecific antibody bone metastasis BRCA cancer immunotherapy cancer treatment chemotherapy clinical trial clinical trials crispr darolutamide docetaxel drug repurposing drug resistance enzalutamide gut microbiome immune checkpoint inhibitors immunotherapy mcrpc metastatic cancer metastatic castration-resistant prostate cancer metastatic hormone-sensitive prostate cancer mHSPC mRNA nanotechnology Nectin-4 oncology personalized medicine prostate cancer PSMA radioligand therapy radiopharmaceuticals real-world data T-cell therapy theranostics
Latest Posts
- Phase 1 for TTX-MC138: Breakthrough RNA Therapeutic Advances in Targeting Metastatic Cancers April 1, 2025
- UPDATE On ENV105: Safety Lead-In Completed for This Innovative Therapy April 1, 2025
- Newsletter 13/2025 March 30, 2025
- New Radiotherapy ATNM-400 Targets Advanced Prostate Cancer March 28, 2025